MAPT and Alzheimer disease: Studies have demonstrated that miR-106b is downregulated in sporadic AD patients as well as in the human neuroblastoma SH-SY5Y cells, and it can inhibit Aβ42-induced tau phosphorylation at the site of Tyr18 (Liu et al., 2016[81]).